Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders

详细信息    查看全文

• 作者：Robert L. Findling ; MD ; MBA¹ ; Robert Goldman ; PhD² ; Yu-Yuan Chiu ; PhD² ; Robert Silva ; PhD² ; Fengbin Jin ; PhD² ; Andrei Pikalov ; MD ; PhD² ; Antony Loebel ; MD² ; ^{antony.loebel@sunovion.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：bipolar I disorder ; lurasidone ; pediatric ; pharmacokinetic ; schizophrenia
• 刊名：Clinical Therapeutics
• 出版年：2015
• 出版时间：1 December 2015
• 年：2015
• 卷：37
• 期：12
• 页码：2788-2797
• 全文大小：309 K

文摘

The aim of this study was to evaluate the pharmacokinetic (PK) profile and tolerability of lurasidone in children and adolescents with a range of psychiatric disorders.

Methods

This multicenter, open-label, single and multiple ascending-dose study of the PK profile of lurasidone (20, 40, 80, 120, and 160 mg/d) enrolled outpatients aged 6 to 17 years with a diagnosis of attention deficit/hyperactivity disorder, bipolar spectrum disorder, or other psychiatric disorder. Serial blood samples were collected for analysis of PK parameters, including C_max, T_max, and AUC_0–24.

Findings

Exposure (C_max and AUC_0–24) to lurasidone and its active metabolites showed linear increases across the entire dose range. Slope estimates (95% CI) across the dose range studied was 0.90 ng · h/mL (0.74–1.06) for AUC_0–24 and 0.70 ng/mL (0.52–0.87) for C_max on day 10 or 12. Lurasidone exposure, after multiple-dose administration in this child and adolescent population, was similar to exposure observed at steady state in adults. The effects of dose on exposure to the 3 active metabolites of lurasidone were linear and similar after the administration of single and multiple doses. Adverse events were qualitatively similar to those reported in adults. Discontinuations due to adverse events were dose related, with doses <120 mg/d being better tolerated than higher doses, especially in younger children.

Implications

In this child and adolescent population, exposure parameters for lurasidone and its active metabolites were dose proportional in the range of 20 to 160 mg/d after the administration of single and multiple doses. These results suggest that lurasidone doses <120 mg/d were better tolerated compared with higher doses, especially in younger children. ClinicalTrials.gov identifier: NCT01620060.